Related Experiment Video

Updated: Jul 19, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation

Oliver Gautschi1, Daniel Ratschiller, Mathias Gugger

  • 1University of California Davis Cancer Center, Sacramento 95817, USA, and Clinic of Medical Oncology, University Hospital Bern, Bern, Switzerland. oliver.gautschi@ucdmc.ucdavis.edu

Lung Cancer (Amsterdam, Netherlands)
|October 31, 2006
PubMed
Abstract

Insights

Cyclin D1 deregulation is pivotal in non-small cell lung cancer (NSCLC) pathogenesis. Overexpression and specific gene variants suggest new diagnostic and therapeutic strategies for lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cyclin D1 (CCND1) is a key regulator of cell cycle progression.
  • Its deregulation is implicated in various cancers, including lung cancer.
  • CCND1 gene amplification and protein overexpression are common in malignancies.

Purpose of the Study:

  • To review evidence linking cyclin D1 deregulation to non-small cell lung cancer (NSCLC) pathogenesis.
  • To explore targeted clinical intervention opportunities for NSCLC.
  • To discuss the role of CCND1 in bronchial neoplasia.

Main Methods:

  • Review of published data up to June 2006.
  • Inclusion of previously unpublished research findings.
  • Analysis of CCND1 gene amplification, protein expression, and mutation status in NSCLC.

Main Results:

  • Cyclin D1 is frequently overexpressed in NSCLC, often from one allele.
  • CCND1 gene amplification occurs in 5-20% of NSCLC tumors.
  • A common CCND1 polymorphism (A870G) affects splicing, producing a variant (cyclin D1b) that may promote malignancy.

Conclusions:

  • Cyclin D1 overexpression is a critical factor in lung cancer development, not merely a consequence.
  • Understanding cyclin D1's role offers potential for novel lung cancer diagnostics and therapeutics.
  • Targeting cyclin D1 pathways may provide new avenues for lung cancer treatment and prevention.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...